616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II

Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations,

A first in human phase 1 Study of cbx 250 a TCR mimetic bispecific T cell engager targeting CG1 HLA a 02 01 in patients with relapsed or refractory AML HR MDS or CMML CROSSCHECK 001 Trial in Progress

Phase l dose escalation and expansion of ziftomenib in combination with quizartinib in AML

Allogeneic CAR T therapy AVC 201 in AML positive for CD123

Phase 1 study of revumenib in combination with intensive chemotherapy IC in patients Pts with newly diagnosed ND Acute Myeloid Leukemia AML harboring genetic alterations in KMT2A NPM1 or NUP98 SNDX 5613 0708

Preliminary results from RIVER 81 a phase 2 study of romaciclib RVU120 venetoclax in patients with acute myeloid leukemia failing first line venetoclax hypomethylating agent HMA

Phase 2 study of SLS009 in combination with azacitidine and venetoclax for relapsed refractory AML with MDS related changes AML MR after prior venetoclax treatment

Pivekimab sunirinine PVEK combined with FLAG IDA for medically fit adults with untreated adverse risk Acute Myeloid Leukemia AML or other high grade myeloid neoplasms NCT06034470

Phase 1 2 study of MP0533 a tetra specific T cell engager CD33 x CD123 x CD70 x CD3 in patients with relapsed refractory AML or MDS AML Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Revumenib for patients with relapsed or refractory R R Nucleophosmin 1–Mutated NPM1m Acute Myeloid Leukemia AML Outcomes by prior treatment in the phase 2 AUGMENT 101 study

Safety tolerability and efficacy of mesutoclax to treat patients with myeloid malignancies